Advanced Liposarcoma Treated Effectively With Common Breast Cancer Therapy

Submitted by admin5 on Tue, 10/17/2017 - 13:30

A recent study compared the safety and efficacy of multiple chemotherapy agents in treating advanced liposarcoma.

A previous stage III study compared therapy with eribulin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Results showed a significant improvement in overall survival (OS) and a manageable toxicity profile for patients receiving eribulin.

George D Demetri, MD, Dana-Farber Cancer Institute (Boston, MA), and colleagues conducted a follow-up histology-specific subgroup analysis of the safety and efficacy of eribulin compared with dacarbazine in patients with liposarcoma. The study consisted of an independently randomized stratified subgroup of the original phase III trial.

Inclusion criteria included age at least 18 years, disease deemed incurable by surgery or radiotherapy, Eastern Cooperative Oncology Group performance status of ≤ 2, and two or more previous systemic treatment regimens (including at least one with anthracycline). Patients were assigned (1:1) to receive eribulin mesylate (1.4 mg/m2 intravenously on days 1 and 8) or dacarbazine (850, 1000, or 1200 mg/m2 intravenously on day 1) every 21 days.

Primary outcomes of the study were OS, progression-free survival (PFS), and safety. Results of the study were published in the Journal of Clinical Oncology (online August 30, 2017; doi:10.1200/JCO.2016.71.6605).


Related Content

FDA Approval Alert: First Therapy for Unresectable Liposarcoma to Show Survival Benefit Approved by FDA

Survivors of Soft-Tissue Sarcoma Face Increased Risk of Hospitalization


Researchers reported that in the liposarcoma subgroup, OS was substantially improved for those receiving eribulin compared with those receiving dacarbazine (15.6 months vs 8.4 months, respectively; HR, 0.51; 95% CI, 0.35-0.75; P < .001). Additionally, researchers observed that eribulin produced longer OS in all liposarcoma histologic subtypes and in every evaluated geographic region.

PFS rates also favored those in the eribulin group (2.9 months vs 1.7 months, respectively; HR, 0.52; 95% CI, 0.35-0.78; P = .0015).

Adverse events were reportedly comparable between the two treatment groups.

Authors of the study concluded that eribulin should be considered an “important treatment option for patients with liposarcoma, a sarcoma subtype for which limited effective systemic treatment are available.” Further research is needed to evaluate eribulin in earlier lines of therapy, as well as in combination with other agents, they wrote.—Zachary Bessette